FAVO Capital Appoints Healthcare Leader Dr. Wael Barsoum to Board of Directors
TL;DR
FAVO Capital gains strategic advantage by appointing healthcare innovation leader Dr. Wael Barsoum to guide its next growth phase with enhanced governance expertise.
FAVO Capital appointed Dr. Wael Barsoum as an independent director, adding decades of healthcare leadership experience to strengthen board oversight and organizational growth strategies.
This appointment strengthens FAVO Capital's ability to support small businesses through alternative funding, contributing to economic growth and sustainable community development.
FAVO Capital brings in a former Cleveland Clinic CEO to its board, blending healthcare innovation expertise with financial services for unique strategic direction.
Found this article helpful?
Share it with your network and spread the knowledge!

FAVO Capital (OTC: FAVO), a diversified financial company operating in financial services and real estate, has appointed Dr. Wael Barsoum to its board of directors as an independent director. The appointment brings significant healthcare leadership experience to FAVO's governance structure as the company continues its expansion across multiple business segments.
Dr. Barsoum brings decades of leadership in healthcare innovation, governance, and organizational growth to FAVO's board. His background includes serving as former president and CEO of Cleveland Clinic Florida and current president and chief transformation officer at Healthcare Outcomes Performance Company. This healthcare expertise represents a strategic addition to FAVO's board composition as the company navigates its next phase of development.
Shaun Quin, president of FAVO Capital, emphasized the significance of this appointment, stating that Barsoum's selection reflects the company's commitment to building a board with the independence, depth, and experience to guide FAVO's next chapter. The move signals FAVO's focus on strengthening corporate governance while bringing diverse industry perspectives to its strategic decision-making process.
FAVO Capital operates across two primary business segments: financial services and selective real assets. Through its financial services division, the company provides alternative, revenue-based funding solutions to small and mid-sized businesses across the United States. Since its inception, FAVO has supported more than 10,000 businesses through the purchase of future receipts, establishing itself as a significant player in the alternative lending space.
Complementing its lending platform, FAVO is building a portfolio of selective real assets that strengthen its balance sheet and broaden its collateral base. The company maintains operations in Florida, New York, and the Dominican Republic, with headquarters located in Fort Lauderdale, Florida. FAVO Capital emphasizes financial transparency, sustainable growth, and long-term value creation for its shareholders as core principles guiding its operations.
Investors can access the latest news and updates relating to FAVO through the company's newsroom at https://nnw.fm/FAVO. The full press release detailing Dr. Barsoum's appointment is available at https://nnw.fm/gLEvl. This board appointment comes at a time when diversified financial companies are increasingly seeking cross-industry expertise to navigate complex market conditions and identify new growth opportunities across different economic sectors.
Curated from InvestorBrandNetwork (IBN)

